Sou Hu Cai Jing·2026-02-24 10:33Core Insights - Pfizer China has secured exclusive commercialization rights for the GLP-1 receptor agonist, Enoglutide, in mainland China through a strategic partnership with Innovent Biologics, which will retain the drug's development, registration, production, and supply responsibilities [2][4] - The partnership is part of Pfizer's response to the rising obesity rates in China, which currently stands at 14.1% among adults, and aligns with the "Healthy China Action" initiative [4] - The GLP-1 drug market in China is becoming increasingly competitive, with multiple companies engaging in price wars, as seen with Novo Nordisk and Eli Lilly significantly reducing prices for their GLP-1 medications [4][5] Company and Industry Summary - Innovent Biologics will receive up to $495 million from Pfizer, which includes upfront payments and milestone payments related to registration and sales [2] - The approval of Enoglutide for diabetes management was granted in January, and its application for long-term weight management is currently under review by the Chinese regulatory authority [2] - The GLP-1 drug class is gaining traction in China, with only a penetration rate of less than 1%, compared to over 10% in the U.S. and 5% in the U.K., indicating significant growth potential in the market [5] - Pfizer's strategy includes diversifying its portfolio beyond COVID-19 products, as evidenced by its recent acquisitions and partnerships aimed at enhancing its presence in the obesity and oncology sectors [6]